Is There an Opportunity to De-Escalate Treatments in Selected Patients with Metastatic Hormone-Sensitive Prostate...

Area of Science:

• Oncology
• Urology

Background:

• Metastatic hormone-sensitive prostate cancer (mHSPC) treatment is dynamic.
• Systemic therapies are the standard of care for mHSPC.
• Prognostic factors like tumor volume and disease presentation influence treatment response.

Purpose of the Study:

• To review the evolving treatment landscape for mHSPC.
• To explore optimal treatment sequencing in mHSPC.
• To assess de-escalation strategies for selected mHSPC patients with favorable profiles.

Main Methods:

• Literature review of current and emerging mHSPC treatment strategies.
• Analysis of prognostic and predictive factors in mHSPC.
• Discussion of ongoing clinical trials investigating treatment intensification and de-escalation.

Main Results:

• The current mHSPC treatment paradigm relies on systemic therapies.
• Tumor burden and disease characteristics are key determinants of treatment efficacy.
• Personalized therapeutic approaches, including intensification and de-escalation, are under investigation.

Conclusions:

• Optimal sequencing of therapies in mHSPC requires further elucidation.
• De-escalation of treatment may be feasible in select mHSPC patients.
• Personalized medicine is crucial for optimizing mHSPC management.